A comprehensive view of Cancer. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.
European Commission approves Merck’s KEYTRUDA pembrolizumab plus chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults
Published:
March 28, 2024
by Business Wire
|
Eli Lilly Japan and Nippon Shinyaku sign alliance for pirtobrutinib in Japan, aiming to supply the drug for mantle cell lymphoma and chronic lymphocytic leukemia treatment; partnership focused on promoting proper use of the drug
Published:
March 27, 2024
by Contify Life Science News
|
Charles River partners with Singapore's Yong Loo Lin School of Medicine to develop and manufacture plasmid DNA for engineered stem cell cancer therapy; partnership to use Charles River's CDMO expertise in HQ and GMP-compliant plasmid DNA
Published:
March 26, 2024
by Zack's Commentary
|
Patent Issued for Antibody-drug-conjugate and its use for the treatment of cancer (USPTO 11918656)
Published:
March 26, 2024
by NewsRx Pharma Business Daily
|
MorphoSys receives US antitrust clearance for its proposed acquisition by Novartis, following clearance in Germany and Austria; the total equity value of the acquisition stands at €2.7B
Published:
March 25, 2024
by ENP Newswire
|
Ask us about our R&D/Patents market view